Gold prices snap 4-day losing streak after Fed rate cut, Trump-Xi meeting
Investing.com -- 4basebio PLC (AIM:4BB) stock surged 6.9% on Monday after announcing that a global Tier 1 pharmaceutical partner has begun dosing patients in Phase I/II clinical trials using the company’s proprietary opDNA® template following FDA approval.
The Cambridge-based synthetic DNA provider revealed that the unnamed pharmaceutical partner is using 4basebio’s technology for an mRNA product, marking a significant milestone in the adoption of synthetic DNA for advanced genetic medicines. The clinical trial follows a supply agreement signed between the companies in April 2024.
4basebio’s opDNA® template, designed specifically for mRNA in-vitro transcription processes, offers significant advantages over traditional plasmid DNA, including reduced costs, higher purity, and shorter production timelines.
This achievement comes after the company received GMP certification from the UK’s Medicines and Healthcare products Regulatory Agency for its late-phase manufacturing facility in April 2025.
The company’s synthetic DNA technology represents a fundamental shift from traditional plasmid DNA production, which faces challenges including lengthy manufacturing timelines and contamination risks.
4basebio’s proprietary platform enables faster, scalable, and cell-free production of DNA templates, potentially accelerating development timelines for cell and gene therapies while offering improved safety and consistency.
Dr. Heikki Lanckriet, 4basebio CEO, noted the achievement represents "another major regulatory milestone for 4basebio and a clear signal of growing industry adoption of synthetic DNA in the use of cell and gene therapies and vaccines."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.